Blood Factors and Diabetic Retinopathy

NCT ID: NCT00005761

Last Updated: 2017-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

173 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-05-23

Study Completion Date

2010-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy.

Patients age 10 years and older with diabetes mellitus and diabetic retinopathy may be eligible for this study. Those enrolled will represent a range of diabetic retinopathy from minimal to severe. Participants will undergo the following procedures:

* medical history
* thorough eye examination
* photographs of the eye
* blood tests to measure blood lipids (cholesterol and triglycerides) and serum creatinine (for kidney function)
* blood tests to measure levels of blood factors (cell adhesion molecules, chemokines and vascular endothelial growth factor) that may be related to the progression of diabetic retinopathy
* blood pressure measurement
* urinalysis

This study may lead to a better understanding of how diabetic retinopathy develops and progresses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants with a range of severity of diabetic retinopathy and healthy volunteers will be evaluated once for serum levels of cell adhesion molecules, chemokines and vascular endothelial growth factor. This study may lead to a better understanding of the pathogenesis of diabetic retinopathy and the identifying of possible targets for treatment. All study participants will undergo an ocular exam and ophthalmic photography. Blood is drawn for the analysis of these serum factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Volunteers will be able to enroll if they:

* Have the ability to understand and sign an informed consent.
* Are able and willing to give a blood sample.
* Are healthy as determined by study Investigator.
* Have no chronic diseases.
* Do not exhibit any clinical indications of diabetes.


Participants will be able to enroll if they:

* Have the ability to understand and sign an informed consent.
* Are able and willing to give a blood sample.
* Have a clinical diagnosis of diabetes based on any one of the following criteria:

1. Documented history of plasma glucose value greater than or equal to 210 mg/dl on three different occasions.
2. Fasting blood sugar greater than or equal to 150 mg/dl on three different occasions.
3. Documented history of ketoacidosis.
4. Insulin dependency.
5. Documented history of abnormal glucose tolerance test.

Exclusion Criteria

Neither volunteers nor participants will be eligible if they:

* Are under the age of 10.
* Have severe systemic disease(s) that compromise our ability to obtain an adequate examination.
* Have any of the following ocular characteristics or conditions in both eyes:

1. Opacities of the ocular media, limitations or pupillary dilation or any other problems sufficient to preclude good, quality stereo fundus photographs.
2. Ocular disease which confounds assessment of diabetic retinopathy such as advanced age-related macular degeneration, central serous choroidopathy, optic atrophy, retinal vein occlusion, active uveitis, significant explained or unexplained visual field loss, or any other type of retinopathy or retinal degeneration.
3. Chronic requirement for any ocular medication for other diseases, such as glaucoma.
Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Eye Institute (NEI)

NIH

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes. 1992 Oct;41 Suppl 2:26-31. doi: 10.2337/diab.41.2.s26.

Reference Type BACKGROUND
PMID: 1526332 (View on PubMed)

Lupu C, Calb M, Ionescu M, Lupu F. Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost. 1993 Oct 18;70(4):579-83.

Reference Type BACKGROUND
PMID: 8115982 (View on PubMed)

Jaffe EA. Cell biology of endothelial cells. Hum Pathol. 1987 Mar;18(3):234-9. doi: 10.1016/s0046-8177(87)80005-9.

Reference Type BACKGROUND
PMID: 3546072 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

00-EI-0135

Identifier Type: -

Identifier Source: secondary_id

000135

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vascular Reparative Mechanism in Diabetes
NCT02119689 ACTIVE_NOT_RECRUITING
Treating Early Stage Diabetic Retinopathy
NCT05132660 ENROLLING_BY_INVITATION EARLY_PHASE1
Diabetic Retinopathy Study (DRS)
NCT00000160 COMPLETED PHASE3
Sorbinil Retinopathy Trial (SRT)
NCT00000159 COMPLETED PHASE3